|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
research. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abou-Alfa GK, Schwartz L, Ricci S, Amadori
D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz
B, et al: Phase II study of sorafenib in patients with advanced
hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomized, double-blind,
placebo-controlled trial. Lancet. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moeini A, Cornellà H and Villanueva A:
Emerging signaling pathways in hepatocellular carcinoma. Liver
Cancer. 1:83–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Santoro A, Rimassa L, Borbath I, Daniele
B, Salvagni S, Van Laethem JL, Van Vlierberghe H, Trojan J, Kolligs
FT, Weiss A, et al: Tivantinib for second-line treatment of
advanced hepatocellular carcinoma: A randomised, placebo-controlled
phase 2 study. Lancet Oncol. 14:55–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Villarroel MC, Rajeshkumar NV,
Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH,
Eshleman JR, Klein A, Laheru D, et al: Personalizing cancer
treatment in the age of global genomic analyses: PALB2 gene
mutations and the response to DNA damaging agents in pancreatic
cancer. Mol Cancer Ther. 10:3–8. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hidalgo M, Bruckheimer E, Rajeshkumar NV,
Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick
MJ, Martell J and Sidransky D: A pilot clinical study of treatment
guided by personalized tumorgrafts in patients with advanced
cancer. Mol Cancer Ther. 10:1311–1316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Das Thakur M, Salangsang F, Landman AS,
Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M and Stuart
DD: Modelling vemurafenib resistance in melanoma reveals a strategy
to forestall drug resistance. Nature. 494:251–255. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gavine PR, Mooney L, Kilgour E, Thomas AP,
Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, et
al: AZD4547: An orally bioavailable, potent, and selective
inhibitor of the fibroblast growth factor receptor tyrosine kinase
family. Cancer Res. 72:2045–2056. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xin H, Wang K, Hu G, Xie F, Ouyang K, Tang
X, Wang M, Wen D, Zhu Y and Qin X: Establishment and
characterization of 7 novel hepatocellular carcinoma cell lines
from patient-derived tumor xenografts. PLoS One. 9:e853082014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhai B and Sun XY: Mechanisms of
resistance to sorafenib and the corresponding strategies in
hepatocellular carcinoma. World J Hepatol. 5:345–352. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Olive KP, Jacobetz MA, Davidson CJ,
Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA,
Caldwell ME, Allard D, et al: Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic
cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sebens S and Schafer H: The tumor stroma
as mediator of drug resistance-a potential target to improve cancer
therapy? Curr Pharm Biotechnol. 13:2259–2272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sausville EA and Burger AM: Contributions
of human tumor xenografts to anticancer drug development. Cancer
Res. 66:3351–3354. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu G, Li F, Ouyang K, Xie F, Tang X, Wang
K, Han S, Jiang Z, Zhu M, Wen D, et al: Intrinsic gemcitabine
resistance in a novel pancreatic cancer cell line is associated
with cancer stem cell-like phenotype. Int J Oncol. 40:798–806.
2012.PubMed/NCBI
|
|
21
|
Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH,
Chen PJ and Cheng AL: Activation of phosphatidylinositol
3-kinase/Akt signaling pathway mediates acquired resistance to
sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther.
337:155–161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Serova M, de Gramont A, Tijeras-Raballand
A, Dos Santos C, Riveiro ME, Slimane K, Faivre S and Raymond E:
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors
in hepatocellular and renal cell carcinoma models developing
resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol.
71:1297–1307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH,
Lin MW, Chen PJ and Chen KF: Dovitinib induces apoptosis and
overcomes sorafenib resistance in hepatocellular carcinoma through
SHP-1-mediated inhibition of STAT3. Mol Cancer Ther. 11:452–463.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Malenstein H, Dekervel J, Verslype C,
Van Cutsem E, Windmolders P, Nevens F and van Pelt J: Long-term
exposure to sorafenib of liver cancer cells induces resistance with
epithelial-to-mesenchymal transition, increased invasion and risk
of rebound growth. Cancer Lett. 329:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sawey ET, Chanrion M, Cai C, Wu G, Zhang
J, Zender L, Zhao A, Busuttil RW, Yee H, Stein L, et al:
Identification of a therapeutic strategy targeting amplified FGF19
in liver cancer by Oncogenomic screening. Cancer Cell. 19:347–358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kornmann M, Ishiwata T, Beger HG and Korc
M: Fibroblast growth factor-5 stimulates mitogenic signaling and is
overexpressed in human pancreatic cancer: Evidence for autocrine
and paracrine actions. Oncogene. 15:1417–1424. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tian X, Chen G, Zhou S, Henne-Bruns D,
Bachem M and Kornmann M: Interactions of pancreatic cancer and
stellate cells are mediated by FGFR1-III isoform expression.
Hepatogastroenterology. 59:1604–1608. 2012.PubMed/NCBI
|
|
28
|
Allerstorfer S, Sonvilla G, Fischer H,
Spiegl-Kreinecker S, Gauglhofer C, Setinek U, Czech T, Marosi C,
Buchroithner J, Pichler J, et al: FGF5 as an oncogenic factor in
human glioblastoma multiforme: Autocrine and paracrine activities.
Oncogene. 27:4180–4190. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang F, Chang RM, Yu L, Lei X, Xiao S,
Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell
proliferation and metastasis by directly targeting FGF5 in
hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tovar V, Cornella H, Moeini A, Vidal S,
Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, et
al: Tumour initiating cells and IGF/FGF signalling contribute to
sorafenib resistance in hepatocellular carcinoma. Gut. 66:530–540.
2017. View Article : Google Scholar : PubMed/NCBI
|
